secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2021-10-04T23:59:59+00:00
Accession:  0001564590-21-049879
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

KalVista stockholders elect three Class III directors at 2021 annual meeting
----------------------------------------------------------------------------

- Elected Albert Cha, Martin Edwards, and Nancy Stuart as Class III directors for three-year terms expiring 2024.
- Ratified Deloitte & Touche as independent auditor for fiscal year ending April 30, 2022: 22.6M for, 13.6K against.
- Approved non-binding advisory vote on named executive officer compensation: 19.7M for, 2.5M against.
- All proposals passed; broker non-votes were 464,900 on director elections and compensation vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000156459021049879/0001564590-21-049879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000156459021049879/kalv-8k_20210930.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-049879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer